AU727080B2 - Calcium blockers to treat proliferative vitreoretinopathy - Google Patents

Calcium blockers to treat proliferative vitreoretinopathy Download PDF

Info

Publication number
AU727080B2
AU727080B2 AU79672/98A AU7967298A AU727080B2 AU 727080 B2 AU727080 B2 AU 727080B2 AU 79672/98 A AU79672/98 A AU 79672/98A AU 7967298 A AU7967298 A AU 7967298A AU 727080 B2 AU727080 B2 AU 727080B2
Authority
AU
Australia
Prior art keywords
compound
patient
glutamate
proliferative vitreoretinopathy
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU79672/98A
Other languages
English (en)
Other versions
AU7967298A (en
Inventor
Evan B Dreyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU7967298A publication Critical patent/AU7967298A/en
Assigned to ALLERGAN SALES, INC. reassignment ALLERGAN SALES, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: Dreyer, Evan B
Application granted granted Critical
Publication of AU727080B2 publication Critical patent/AU727080B2/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. Alteration of Name(s) in Register under S187 Assignors: ALLERGAN SALES, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU79672/98A 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy Ceased AU727080B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5196297P 1997-06-30 1997-06-30
US60/051962 1997-06-30
PCT/US1998/012414 WO1999000129A1 (en) 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy

Publications (2)

Publication Number Publication Date
AU7967298A AU7967298A (en) 1999-01-19
AU727080B2 true AU727080B2 (en) 2000-11-30

Family

ID=21974492

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79672/98A Ceased AU727080B2 (en) 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy

Country Status (6)

Country Link
US (4) US6380261B1 (https=)
EP (1) EP0994709A4 (https=)
JP (1) JP2002511868A (https=)
AU (1) AU727080B2 (https=)
CA (1) CA2295098A1 (https=)
WO (1) WO1999000129A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994709A4 (en) * 1997-06-30 2006-02-01 Allergan Inc CALCIUM BLOCKER FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
WO2000007584A2 (en) * 1998-08-04 2000-02-17 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
US6509355B1 (en) * 1998-10-27 2003-01-21 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
CA2356382A1 (en) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
NZ550088A (en) * 2004-04-06 2009-08-28 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
WO2006033020A2 (en) * 2004-04-26 2006-03-30 Rosetta Genomics Ltd. Methods and apparatus for the detection and validation of micrornas
US7122128B2 (en) * 2004-04-29 2006-10-17 General Electric Company Phosphors containing borate of terbium, alkaline-earth, and Group-3 metals, and light sources incorporating the same
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
CA2573668A1 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
EP1776097A1 (en) * 2004-07-26 2007-04-25 Allergan, Inc. Methods of treating ophthalmic conditions
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
CN106572988B (zh) 2014-04-08 2022-04-08 卫理公会医院 Inos抑制性组合物及其作为乳腺癌治疗剂的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
WO1990006123A1 (en) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5521215A (en) 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
FR2717080B1 (fr) 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5431907A (en) * 1994-08-03 1995-07-11 Abelson; Mark B. Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents
US5604244A (en) 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
FR2738567B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
SI0848707T1 (en) 1995-09-08 2000-02-29 Sanofi-Synthelabo 4-(cycloalkyl)piperidines and 4-(cycloalkylalkyl)-piperidines derivatives, preparation thereof and therapeutical applications thereof
FR2738568B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de 4-(cycloalkyl)piperidines et 4-(cycloalkylalkyl) piperidines, leur preparation et leur application en therapeutique
EP0994709A4 (en) 1997-06-30 2006-02-01 Allergan Inc CALCIUM BLOCKER FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY
US6509355B1 (en) 1998-10-27 2003-01-21 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCIENCE 248:597-603 (1992) *
TRENDS PHARMACOLOGICAL SCIENCES 13:291-296 (1992) *

Also Published As

Publication number Publication date
US20050192322A1 (en) 2005-09-01
CA2295098A1 (en) 1999-01-07
US7230032B2 (en) 2007-06-12
EP0994709A1 (en) 2000-04-26
US6573280B2 (en) 2003-06-03
AU7967298A (en) 1999-01-19
EP0994709A4 (en) 2006-02-01
US20030060510A1 (en) 2003-03-27
US8101635B2 (en) 2012-01-24
WO1999000129A1 (en) 1999-01-07
US6380261B1 (en) 2002-04-30
JP2002511868A (ja) 2002-04-16
US20030199551A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
AU727080B2 (en) Calcium blockers to treat proliferative vitreoretinopathy
CA2150933C (en) Glaucoma treatment
US6482854B1 (en) Glaucoma treatment
US5506231A (en) Treatment of aids dementia, myelopathy and blindness
McNamara et al. Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models
Winger et al. Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action
DE69434872T2 (de) Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
AU740504B2 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
US20020068072A1 (en) Use of a substance p antagonist in a pharmaceutical composition
Siegner et al. Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye
EP0557290A4 (en) TREATMENT OF AIDS-ASSOCIATED DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY AND VISUAL LOSS.
EP0434173A2 (de) Verwendung von NMDA-Rezeptor-Antagonisten zur Behandlung chronischer neurodegenerativer Erkrankungen
US20050009884A1 (en) Calcium blockers to treat proliferative retinal diseases
BÄRÄNY Pilocarpine‐induced subsensitivity to carbachol and pilocarpine of ciliary muscle in vervet and cynomolgus monkeys
Lal et al. A comparison of the antidiarrheal and some other pharmacological effects of clonidine, lidamidine, and loperamide in the rat
Shelton Substitution profiles of N-methyl-D-aspartate antagonists in ethanol-discriminating inbred mice
Patil et al. Mechanism of vascular relaxation by cholinomimetic drugs with special reference to pilocarpine and arecoline
OSTERGARD The effect of drugs on the lower urinary tract
Azzaro et al. Drugs used in mood disorders
Turner et al. Antihistamines
Flach Ophthalmic Clinical Pharmacology Reiview: Epinephrine and the Therapy of the Glaucomas
Negherbon et al. Handbook of Toxicology: Tranquilizers
Maxwell The pharmacological rationale for bupropion
WO2011000562A1 (en) Eltoprazine for the treatment of certain movement disorders
Waters et al. Respiratory and circulatory effects of centrally administered phencyclidine in anesthetized dogs

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Free format text: ALLERGAN SALES, INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALLERGAN, INC

Free format text: FORMER OWNER WAS: ALLERGAN SALES, INC.